Healthcare / BiotechnologyTaipei Exchange
$43.90
-1.25 (-2.77%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 25%
FCF escenarios
weak_data · normalized FCF $-296.2M · quality 81.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
21/100
D
Piotroski
3/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$3.9B
P/E
N/A
•EV/EBITDA
N/A
•ROE
-34.8%
↓Gross Margin
48.6%
↑Debt/Equity
0.03
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+2.3%
FCF CAGR
—
FCF margin
-23246.4%
FCF / Net income
0.94x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $1.1M · net income $-264.8M · FCF $-248.7M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $1.1M | $1.1M | $1.0M | $1.0M | $1.0M |
| Net Income | $-264.8M | $-264.8M | $-293.7M | $-296.3M | $-349.6M |
| EBITDA | $-250.6M | $-250.6M | $-279.7M | $-283.8M | $-340.6M |
| EPS | — | — | -3.29 | -3.32 | -3.92 |
| Gross Margin | 48.6% | 48.6% | 47.7% | 55.2% | 50.5% |
| Operating Margin | -26005.5% | -26005.5% | -30619.1% | -31111.1% | -35611.5% |
| Net Margin | -24744.8% | -24744.8% | -29374.5% | -29630.6% | -34963.2% |
| Balance Sheet | |||||
| Debt/Equity | 0.03 | 0.03 | 0.01 | 0.01 | 0.01 |
| Current Ratio | 17.21 | 17.21 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-248.7M | $-248.7M | $-296.2M | $-299.2M | $-400.3M |
| Returns | |||||
| ROE | -34.8% | -34.8% | -28.6% | -22.5% | -21.7% |
| Valuation | |||||
| P/B | 5.16 | 5.16 | 3.67 | 3.45 | 3.21 |
| Growth & Yield | |||||
| Revenue Growth | 7.0% | 7.0% | 0.0% | 0.0% | — |
| EPS Growth | — | — | 0.9% | 15.3% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+24.5%
Start / end P/E
n/dx → n/dx
EPS bridge
-3.29 → n/d
Residual
+24.5%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.